272 related articles for article (PubMed ID: 22517037)
1. A case report of T cell prolymphocytic leukemia and Kaposi sarcoma and a review of T cell prolymphocytic leukemia.
Paul RN; Alizadeh L; Ajayi OI; Karpurapu H; Ganesan C; Taddesse-Heath L; Aggarwal A
Acta Haematol; 2012; 127(4):235-43. PubMed ID: 22517037
[TBL] [Abstract][Full Text] [Related]
2. T-cell prolymphocytic leukemia.
Dearden CE
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S239-43. PubMed ID: 19778847
[TBL] [Abstract][Full Text] [Related]
3. T-cell prolymphocytic leukaemia (T-PLL): a rare disease with a grave prognosis.
Vivekanandarajah A; Atallah JP; Gupta S
BMJ Case Rep; 2013 May; 2013():. PubMed ID: 23645660
[TBL] [Abstract][Full Text] [Related]
4. Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience.
Damlaj M; Sulai NH; Oliveira JL; Ketterling RP; Hashmi S; Witzig T; Nowakowski G; Call TG; Shanafelt TD; Ding W; Hogan WJ; Litzow MR; Patnaik MM
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):699-704. PubMed ID: 26422251
[TBL] [Abstract][Full Text] [Related]
5. Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment.
Collignon A; Wanquet A; Maitre E; Cornet E; Troussard X; Aurran-Schleinitz T
Curr Oncol Rep; 2017 Apr; 19(4):29. PubMed ID: 28324286
[TBL] [Abstract][Full Text] [Related]
6. T-cell prolymphocytic leukemia: A rare disease in an elderly female.
Madaris L
J Am Acad Nurse Pract; 2010 Dec; 22(12):648-53. PubMed ID: 21129072
[TBL] [Abstract][Full Text] [Related]
7. T-cell prolymphocytic leukemia.
Khot A; Dearden C
Expert Rev Anticancer Ther; 2009 Mar; 9(3):365-71. PubMed ID: 19275513
[TBL] [Abstract][Full Text] [Related]
8. Immunophenotypic characterization of T-cell prolymphocytic leukemia.
Chen X; Cherian S
Am J Clin Pathol; 2013 Nov; 140(5):727-35. PubMed ID: 24124154
[TBL] [Abstract][Full Text] [Related]
9. T-cell prolymphocytic leukemia: an aggressive T cell malignancy with frequent cutaneous tropism.
Magro CM; Morrison CD; Heerema N; Porcu P; Sroa N; Deng AC
J Am Acad Dermatol; 2006 Sep; 55(3):467-77. PubMed ID: 16908353
[TBL] [Abstract][Full Text] [Related]
10. T-cell prolymphocytic leukemia: update and focus on alemtuzumab (Campath-1H).
Cao TM; Coutre SE
Hematology; 2003 Feb; 8(1):1-6. PubMed ID: 12623420
[TBL] [Abstract][Full Text] [Related]
11. Current treatment options in prolymphocytic leukemia.
Robak T; Robak P
Med Sci Monit; 2007 Apr; 13(4):RA69-80. PubMed ID: 17392661
[TBL] [Abstract][Full Text] [Related]
12. TCL-1-positive hematogones in a patient with T-cell prolymphocytic leukemia after therapy.
Hu Z; Li S; Medeiros LJ; Sun T
Hum Pathol; 2017 Jul; 65():175-179. PubMed ID: 28232160
[TBL] [Abstract][Full Text] [Related]
13. B- and T-cell prolymphocytic leukemia: antibody approaches.
Dearden C
Hematology Am Soc Hematol Educ Program; 2012; 2012():645-51. PubMed ID: 23233647
[TBL] [Abstract][Full Text] [Related]
14. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.
Dearden CE; Matutes E; Cazin B; Tjønnfjord GE; Parreira A; Nomdedeu B; Leoni P; Clark FJ; Radia D; Rassam SM; Roques T; Ketterer N; Brito-Babapulle V; Dyer MJ; Catovsky D
Blood; 2001 Sep; 98(6):1721-6. PubMed ID: 11535503
[TBL] [Abstract][Full Text] [Related]
15. Unusually indolent T-cell prolymphocytic leukemia associated with a complex karyotype: is this T-cell chronic lymphocytic leukemia?
Soma L; Cornfield DB; Prager D; Nowell P; Bagg A
Am J Hematol; 2002 Nov; 71(3):224-6. PubMed ID: 12410582
[TBL] [Abstract][Full Text] [Related]
16. Guillain-Barré syndrome after use of alemtuzumab (Campath) in a patient with T-cell prolymphocytic leukemia: a case report and review of the literature.
Abbi KK; Rizvi SM; Sivik J; Thyagarajan S; Loughran T; Drabick JJ
Leuk Res; 2010 Jul; 34(7):e154-6. PubMed ID: 20362332
[No Abstract] [Full Text] [Related]
17. Long-Smoldering T-prolymphocytic Leukemia: A Case Report and a Review of the Literature.
Gjelberg HK; Helgeland L; Liseth K; Micci F; Sandnes M; Russnes HG; Reikvam H
Curr Oncol; 2023 Nov; 30(11):10007-10018. PubMed ID: 37999147
[TBL] [Abstract][Full Text] [Related]
18. Loss of donor chimerism in remission after allogeneic stem cell transplantation of T-prolymphocytic leukemia patients following alemtuzumab induction therapy.
Szuszies CJ; Hasenkamp J; Jung W; Koch R; Trümper L; Wulf GG
Int J Hematol; 2014 Nov; 100(5):425-8. PubMed ID: 25258193
[TBL] [Abstract][Full Text] [Related]
19. Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study.
Krishnan B; Else M; Tjonnfjord GE; Cazin B; Carney D; Carter J; Ketterer N; Catovsky D; Ethell M; Matutes E; Dearden CE
Br J Haematol; 2010 Jun; 149(6):907-10. PubMed ID: 20201944
[No Abstract] [Full Text] [Related]
20. Conjunctival involvement with T-cell prolymphocytic leukemia: report of a case and review of the literature.
Lee SS; Robinson MR; Morris JC; Mirtsching BC; Shen D; Chan CC
Surv Ophthalmol; 2004; 49(5):525-36. PubMed ID: 15325197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]